.Pharmacolibrary.Drugs.ATC.N.N03AF04

Information

Eslicarbazepine is an anticonvulsant drug used primarily as adjunctive therapy for partial-onset seizures in adults with epilepsy. It is the active metabolite of eslicarbazepine acetate and acts mainly as a voltage-gated sodium channel blocker. Eslicarbazepine is approved in several countries, including under the trade name Zebinix or Aptiom.

Pharmacokinetics

Pharmacokinetic parameters reported for healthy adult volunteers (mixed sex) after oral administration of eslicarbazepine acetate, reporting data for the active metabolite eslicarbazepine.

References

1. Gidal, BE, et al., & Sunkaraneni, S (2018). Exposure-safety and efficacy response relationships and population pharmacokinetics of eslicarbazepine acetate. Acta neurologica Scandinavica 138(3) 203–211. DOI:10.1111/ane.12950 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29732549

2. Jacob, S, & Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. Drugs in R&D 16(4) 303–316. DOI:10.1007/s40268-016-0148-6 PUBMED:https://pubmed.ncbi.nlm.nih.gov/27766590

3. Sunkaraneni, S, et al., & Fiedler-Kelly, J (2018). Population Pharmacokinetics and Exposure-Response Analyses of Eslicarbazepine Acetate Efficacy and Safety in Monotherapy of Partial-Onset Seizures. Journal of clinical pharmacology 58(7) 927–938. DOI:10.1002/jcph.1086 PUBMED:https://pubmed.ncbi.nlm.nih.gov/29528499

Revisions

• 06/2025 initial generated model